Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group plc.
Mission Therapeutics appoints Dr Bobby Soni to its Board of Directors
Bobby is currently Director of Healthcare Investments at Touchstone Innovations, now part of the IP Group plc. He joined Touchstone Innovations (previously Imperial Innovations) in 2015 from Novo Seeds, the early stage investment arm of Novo AS where he worked as Investment Director. Bobby has 17 years’ experience in the Life Science industry covering drug development, business development and venture capital investment. He is a Non-Executive Director of Storm Therapeutics, Enterprise Therapeutics, Artios Pharma, Pulmocide, and Autifony.
Bobby has a PhD in Biology from the University of Virginia and an undergraduate degree in Biochemistry from the University of Rochester.
Commenting on the appointment, Dr Anker Lundemose, Mission’s CEO, said:
“On behalf of the Board I am pleased to welcome Bobby to the Board of Mission Therapeutics. His strong life sciences background and range of experiences within the pharmaceutical and biotechnology sectors will be invaluable as Mission builds its pipeline of first-in-class therapeutic assets across multiple serious disease areas. I would also like to thank Rob for his valuable contribution to Mission and wish him every success in the future.”
MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.